Cisplatin-DNA adduct formation in maternal and fetal rat tissues after transplacental cisplatin exposure

Carcinogenesis

Volumn 17, Issue 8, 1996, Pages 1665-1669

  Giurgiovich, A J ^a   Diwan, B A ^b   Lee, K B ^a   Anderson, L M ^c   Rice, J M ^c   Poirier, M C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOGEN; CISPLATIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; BLOOD PLACENTA BARRIER; BRAIN; CANCER INCIDENCE; DNA ADDUCT; DNA DAMAGE; DOSE RESPONSE; DRUG DNA BINDING; FEMALE; FETUS; FETUS LIVER; FLUOROIMMUNOASSAY; GENOTOXICITY; INTRAPERITONEAL DRUG ADMINISTRATION; LIVER; NEPHROTOXICITY; NONHUMAN; PLACENTA; PLACENTAL TRANSFER; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; RAT; TRANSPLACENTAL CARCINOGENESIS;

EID: 0029778728     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/17.8.1665     Document Type: Article

References (33)

1. DuBeshter, B., Lin, J., Angel, C. and Poulter, C.A. (1993) Gynecologic tumors. In Rubin, P. (ed.), Clinical Oncology: A Multidisciplinary Approach far Physicians and Students. W.B.Saunders, Philadelphia.
2. Greene, M.H. (1992) Is cisplatin a human carcinogen? J. Natl Cancer Inst., 84, 306-312.
3. Christman, J.E., Teng, N.N., Lebovic, G.S. and Sikic, B.I. (1990) Delivery of a normal infant following cisplatin, vinblastine, and bleomycin (PVB) chemotherapy for malignant teratoma of the ovary during pregnancy. Gynecol. Oncol., 37, 292-295.
4. Malfetano, J.H. and Goldkrand, J.W. (1990) Cis-platinum combination chemotherapy during pregnancy for advanced epithelial ovarian carcinoma. Obstet. Gynecol., 75, 545-547.
5. Barnhart, K.M. and Bowden, G.T. (1985) Cisplatin as an initiating agent in two-stage mouse skin carcinogenesis. Cancer Lett., 29, 101-105.
6. Leopold, W.R., Miller, E.C. and Miller, J.A. (1979) Carcinogenicity of antitumor cis-platinum (II) coordination complexes in the mouse and rat. Cancer Res., 39, 913-918.
7. Hennings, H., Shores, R.A., Poirier, M.C., Reed, E., Tarone, R.E. and Yuspa, S.H. (1990) Enhanced malignant conversion of benign mouse skin tumors by cisplatin. J. Natl Cancer Inst., 82, 836-840.
8. Eastman, A. (1983) Characterization of the adducts produced in DNA by cis-diamminedichloroplatinum (II) and cis-dichloro(ethylene-diammine)-platinum (II). Biochemistry, 22, 3927-3933.
9. Reedijk, J. and Lohman, P.H.M. (1985) Cisplatin: synthesis, antitumour activity and mechanism of action. Pharm. Weekbl. Sci., 7, 173-180.
10. 195Pt NMR kinetic and mechanistic studies of cis- and trans-diamminedichloroplatinum(II) binding to DNA. J. Am. Chem. Soc., 112, 6860-6871.
11. Bernges, F. and Holler, E. (1995) The reaction of platinum(II) complexes with DNA. Kinetics of intrastrand crosslink formation in vitro. Nucleic Acids Res., 19, 1483-1489.
12. Dijt, F.J., Fichtinger-Schepman, A.M., Berends, F. and Reedijk, J. (1988) Formation and repair of cisplatin-induced adducts to DNA in cultured normal and repair-deficient human fibroblasts. Cancer Res., 48, 6058-6062.
13. Pinto, A.L. and Lippard, S.J. (1985) Sequence-dependent termination of in vitro DNA synthesis by cis- and trans-diamminedichloroplatinum (II). Proc. Natl Acad. Sci. USA, 82, 4616-4619.
14. Comess, K.M., Burstyn, J.N., Essigmann, J.M. and Lippard, S.J. (1991) Replication inhibition and translesion synthesis on templates containing site-specifically placed cis-diamminedichloroplatinum(II) DNA adducts. Biochemistry, 31, 3975-3990.
15. Beck, D.J. and Fisch, J.E. (1980) Mutagenicity of platinum coordination complexes in Salmonella typhimurium. Mutat. Res., 77, 45-54.
16. Taylor, R.T., Carver, J.H., Hanna, M.L. and Wandres, D.L. (1979) Platinum-induced mutations to 8-azaguanine resistance in Chinese hamster ovary cells. Mutat. Res., 67, 65-80.
17. Bradley, L.J., Yarema, K.J., Lippard, S.J. and Essigmann, J.M. (1993) Mutagenicity and genotoxicity of the major DNA adduct of the antitumor drug cis-diamminedichloroplatinum(II). Biochemistry, 32, 982-988.
18. Diwan, B.A., Anderson, L.M., Rehm, S. and Rice, J.M. (1993) Transplacental initiation of skin tumors of cis-diammine-dichloroplatinum in SENCAR mice. Proc. Am. Assoc. Cancer Res., 34, 182, (abstract).
19. Diwan, B.A., Anderson, L.M., Ward, J.M., Henneman, J.R. and Rice, J.M. (1995) Transplacental carcinogenesis by cisplatin in F344/NCr rats: promotion of kidney tumors by postnatal administration of sodium barbital. Toxicol. Appl. Pharmacol., 132, 115-121.
20. Flamm, W.G., Birnstiel, M.L. and Walker, P.M.B. (1967) Preparation and fractionation and isolation of single strands of DNA by ultracentrifugation in fixed-angle rotors. In Birnie, G.D. and Fox, S.M. (eds), Subcellular Components: Preparation and Fractionation. Butterworths and Company Ltd, London, pp. 126-154.
21. Olivero, O.A., Semino, C., Kassim, A., Lopez-Larraza, D.M. and Poirier, M.C. (1995) Preferential binding of cisplatin to mitochondrial DNA of Chinese hamster ovary cells. Mutat. Res., 346, 221-230.
22. Shamkhani, H., Anderson, L.M., Henderson, C.E. et al. (1994) DNA adducts in human and patas monkey maternal and fetal tissues induced by platinum drug chemotherapy. Reprod. Toxicol., 8, 207-216.
23. Schoket, B., Doty, W.A., Vincze, I., Strickland, P.T., Assennato, G. and Poirier, M.C. (1993) Increased sensitivity for determination of polycyclic aromatic hydrocarbon - DNA adducts in human DNA samples by dissociation-enhanced lanthanide fluoroimmunoassay (DELFIA). Cancer Epidemiol. Biomed. Prev., 2, 349-353.
24. Poirier, M.C. Lippard, S.J., Zwelling, L.A., Ushay, H.M., Kerrigan, D., Thill, C.C., Santella, R.M., Grunberger, D. and Yuspa, S.H. (1982) Antibodies elicited against cis-diamminedichloroplatinum(II)-modified DNA are specific for cis-diamminedichloroplatinum(II)-DNA adducts formed in vivo and in vitro. Proc. Natl Acad. Sci. USA, 79, 6443-6447.
25. Reed, E., Gupta-Burt, S., Litterst, C.L. and Poirier, M.C. (1990) Characterization of the DNA damage recognized by an antiserum elicited against cis-diamminedichloroplatinum (II)-modified DNA. Carcinogenesis, 11, 2117-2121.
26. Kriek, E., den Engelse, L., Scherer, E. and Westra, J.G. (1984) Formation of DNA modifications by chemical carcinogens. Identification, localization and quantification. Biochim. Biophys. Acta, 738, 181-201.
27. Reed, E., Sauerhoff, S. and Poirier, M.C. (1988) Quantitation of platinum-DNA binding after therapeutic levels of drug exposure. Atomic Spectrosc., 9, 93-95.
28. Stewart, D.J., Benjamin, R.S., Luna, M., Feun, L., Caprioli, R., Seifert, W. and Loo, T.L. (1982) Human tissue distribution of platinum after cis-diamminedichloroplatinum. Cancer Chemo. Pharmacol., 10, 51-54.
29. Dobyan, D.C., Levi, J., Jacobs, C., Kosek, J. and Weiner, M.W. (1980) Mechanism of cis-platinum nephrotoxicity: II. Morphologic observations. J. Pharmacol. Exp. Ther., 213, 551-556.
30. Guarino, A.M., Miller, D.S., Arnold, S.T., Pritchard, J.B., Davis, R.D., Urbanek, M.A., Miller, T.J. and Litterst, C.L. (1979) Platinate toxicity: past, present, and prospects. Cancer Treat. Rep., 63, 1475-1483.
31. Farris, F.F., King, F.G., Dedrick, R.L. and Litterst, C.L. (1985) Physiological model for the pharmacokinetics of cis-dichlorodiammineplatinum (II) (DDP) in the tumored rat. J. Pharmacokinet. Biopharm., 13, 13-39.
32. Poirier, M.C., Reed, E., Litterst, C.L., Katz, D. and Gupta-Burt, S. (1992) Persistence of platinum-ammine-DNA adducts in gonads and kidneys of rats and multiple tissues from cancer patients. Cancer Res., 52, 149-153.
33. Henderson, C.E., Elia, G., Garfinkel, D., Poirier, M.C., Shamkhani, H. and Runowicz, C.D. (1993) Platinum chemotherapy during pregnancy for serous cystadenocarcinoma of the ovary. Gynecol. Oncol., 49, 92-94.